Cancer Patients with ACA Policies Swiftly Reach Out-of-Pocket Caps

Contact: Sarah Avery Phone: 919-660-1306 Email: ASCO Abstract #6504 FOR IMMEDIATE RELEASE on Saturday, June 4, 2016 DURHAM, N.C. – A hypothetical leukemia patient buying the life-extending drug therapy for his condition would reach his annual out-of-pocket maximum in a month on most of the bronze policies and half of the silver policies offered through the Affordable Care Act marketplace.    The findings, reported by researchers at the Duke Cancer Institute at the American Society of Clinical Oncology meeting in Chicago (Abstract #6504), found that cancer patients buying health insurance coverage through the Affordable Care Act marketplace should take into account annual premiums, out-of-pocket maximums, and potential treatment costs – not just one or another of those factors. Even then, the coverage level did not necessarily predict the amount of expected out-of-pocket costs. “When when using all those criteria, the least expensive choice for patients was often the lower tier policies -- typically sold as the “bronze” option -- but not always,” said senior author Yousuf Zafar, M.D., associate professor in the School of Medicine and the Sanford School of Public Policy at Duke University. “Patients might assume that the bronze policy would be the least expensive compared to silver or gold levels, but it’s important to shop carefully, particularly when considering out-of-po...
Source: Duke Health Features - Category: Pediatrics Tags: Duke Medicine Source Type: news

Related Links:

By CHADI NABHAN, MD, MBA, FACP “The goal for me and for my clinical and research colleagues is to put ourselves out of a job as quickly as possible”. This is how Mikkael Sekeres ends his book “When Blood Breaks Down” based on true stories of patients with leukemia. I share Mikkael’s sentiments and have always stated that I’d be happy if I am out of a job caring for patients with cancer. To his and my disappointment, this wish is unlikely to ever come true, especially when dealing with leukemia. With almost 15 years of experience, Sekeres possesses a wealth of knowledge and pati...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Medical Practice Physicians Book Review Chadi Nabhan hematology Mikkael Sekeres Oncology When Blood Breaks Down Source Type: blogs
The objective of this study was to analyze potential drug interactions (PDIs) between targeted OAAs and concomitant therapy in clinical practice. METHODS: A cross-sectional observational study was performed in cancer outpatients who started treatment with a targeted OAA between December 1st 2015 and May 31st 2019. PDIs were analyzed using the Lexicomp® website and the database About Herbs®. PDIs were classified according to severity, risk, and reliability ratings and their underlying mechanism. Univariate and multivariate analysis were performed to identify risk factors associated with PDIs. RESULTS: A tota...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Circular RNAs (circRNAs), which act as initiators and promoters of various diseases, were thought to be mostly noncoding RNAs (ncRNAs) in eukaryotes, until recent studies confirmed that some circRNAs have the function of encoding proteins. Accumulating research findings have proved that dysregulation of circRNAs is associated with the developmental process of multiple cancers. circHIPK3, an example of circRNA, is frequently expressed in many diseases, such as diabetes, age-related cataract, idiopathic pulmonary fibrosis, preeclampsia, osteoblasts, and retinal vascular dysfunction, leading to disease development and progres...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: The increasing use of oral anti-cancer drugs confronts patients and treatment teams with special challenges. To optimize treatment outcomes, a multidisciplinary approach should be taken, involving physicians, pharmacists, and nurses. To improve medication safety, medication and side-effect management should be performed, and adherence should be regularly checked and systematically encouraged. PMID: 31920193 [PubMed - in process]
Source: Deutsches Arzteblatt International - Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research
ConclusionTaken together, our results indicate that administration of CUDC-907, a dual PI3K and HDAC inhibitor, may be an effective strategy against ABL TKI-resistant cells, including cells harboring the T315I mutation. Moreover, CUDC-907 may enhance the cytotoxic effects of ABL TKI when a combined treatment strategy is used against Philadelphia chromosome-positive leukemia cells.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: A dramatic shift was seen in CML treatments away from traditional, nonoral chemotherapy toward use of novel oral TKIs between 2000 and 2017. As the costs of oral anticancer agents reach new highs, studies assessing the long-term health and financial outcomes among patients with CML are warranted. PMID: 31590146 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Conclusion.This is a novel decision that will become more common as the prevalence of patients with well‐controlled CML continues to increase. These results highlight the need for patient education and decision support so that patients and providers can make shared decisions that are informed and values based.Implications for Practice.The standard treatment for chronic phase chronic myeloid leukemia (CML) is lifelong oral tyrosine kinase inhibitor (TKI) therapy. Clinical trials have shown that some patients with a sustained deep molecular response to TKI therapy can safely stop therapy and remain in a treatment‐free re...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Leukemias, Symptom Management and Supportive Care, Hematologic Malignancies, Health Outcomes and Economics of Cancer Care Source Type: research
CONCLUSION: Imatinib with low-dose ara-c can be considered as a potential first-line treatment option for CML-CP.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
In conclusion, e-As4S4 holds great potential for an alternative therapeutics in the treatment of breast cancer, due to its unique function of correcting the aggressive microenvironment. Introduction Metastasis is the leading cause of breast cancer mortality, which has been one major challenge in clinical treatment (1). In particular, triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptors (ER), progesterone receptors (PR) and HER2 receptors, which is one of the most aggressive types of breast cancers, marked by high rates of relapse, visceral metastases and early death (2, 3). The...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Qingbin Cui1,2, Chao-Yun Cai2, Hai-Ling Gao2,3, Liang Ren1, Ning Ji2,4, Pranav Gupta2, Yuqi Yang2, Suneet Shukla5, Suresh V. Ambudkar5, Dong-Hua Yang2 and Zhe-Sheng Chen2* 1School of Public Health, Guangzhou Medical University, Guangdong, China 2Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States 3Department of Histology and Embryology, Clinical Medical College, Weifang Medical University, Weifang, China 4Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tian...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chronic Leukemia | Chronic Myeloid Leukaemia | Funding | Gleevec | Health | Health Insurance | Health Management | Insurance | Leukemia | Oral Cancer | Pediatrics | Study